Cite

    Calabrese, M. et al. (2017). Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. Journal of neurology, neurosurgery and psychiatry. 88 (12), pp. 1073-1078. [Online].